industry

Cassava Sciences Inc

action

The day to day price action of this limp dick is more painful to watch than slugs breeding.

$SAVA , this daily one way action is depressing.

Zero confidence in management based on both recent actions and historical issues with the FDA. 2.

$SAVA We may get frustrated with volatility, manipulation, and irregular daily price action

price

This is sickening that these crooks can manipulate the price like this. !!!

He invites shorts to destroy stock price.. pathetic!

Some had to drop in price a little first!

new employee mr. cook must be pissed as this is lower price than the shares he got it for.

All.u did was dilute the pps 
..and release to prs to kill the stock price and momentum  
 You did so well..you fxuking scumbag.

I hate the stock price runup leading to an announcement.

data

- 
$AVXL in comparison, boring as hell - whenever Missling talks people fall asleep and holding back data and further readouts without any logical explanation are red flags -

$SAVA 
Pyggie here was bullish a few days ago, folded like a pussy because he can’t read data, and now spews FUD, like a spoiled child, because he’s worried he may have paper-handed a monster.

but offer only the “opinion” that there was “possible data manipulation.”

$SAVA longtime biotech investor and my honest experience when a CEO promises good data and there is a long waiting period = not good.

Sentiment matters in this game, and unfortunately, this company has been drug through the mud for so long that good data might just get overlooked.

$SAVA The ironic and sad thing is that this ticker has been abused and manipulated so badly that even if it triples on upcoming data release it still won&#39;t come close to ATH achieved on much less evidence of safety and efficacy.

The CEO belongs in jail with all this pump and dump stock manipulation and data manipulation

just annoying we all get so worked up and insulting when we, the retail investor, can neither move Remi to release data early or in truth, move the SP by buying or selling a few hundred shares.

$SAVA dumb management causing longs to lose confidence, you dont change the date of data release every few weeks, just give a date when you are certain and stick with that, its that simple

BIIB with a 27% chance of no decline - so bad, how can they even publish data like that.

patient

however, if you are a family member of Alz patient think about how fatiguing emotionally and financially it is to change diapers, have your name forgotten, or even have to take a license away from an otherwise healthy person.

but your day will come when you will pay back way more than the damage you have caused and the lives you have threatened from being treated for a debilitating disease.

$ALZN $ATHA $ORMP $SAVA $SPRC yes then go back to your scam board clown no need to trap others in this scam .. we know what value SAVA brings to their AD patients

Lecanemab approved - IV  infusion..increased infection risk, inconvenient for patients with MD&#39;s fully aware 
of side effects: brain swelling and bleeding. 2.

Eventually, the  
AD patient is unable to perform daily functions.

But the monoclonal antibody treatment also carries risks of brain swelling and bleeding.

$BIIB - lied and tried to push their bad drug Aduhelm on unsuspecting patients (one of which is a family member of mine).

3 deaths in 1900 trial patients.. how many deaths is our FDA going to inflict on millions of folks who are supposed to take this death drugs that also happen to have near-zero efficacy?? SMH

Avxl, not good they didn&#39;t have an agreement in place “plan for approval“ before they started the test fase 2b 500 patients.

$SAVA It&#39;s not only CRUEL for anyone to be prescribing any of these MABs for AD patients, it&#39;s impractical for both patients and the healthcare system in general.

application

$SAVA Words  to  to  ignorant,  never  hype  a  employee  from  fda,  shady  shiat! 🤡🤡🤡😂😂😂

It doesn&#39;t matter if drugs for terminal illnesses, have been approved after 6 months, because there is endless manipulation here, and this waiting game is based on either FDA approval or denial based on corruption at the agency?

This is such crap with the FDA my Father died a year ago from it

$BIIB $SAVA You would need uncommon patience to not be crazy mad at the system for this shenanigan approval process and decision from the FDA.

Idiots with no respect for integrity continues  to run 
wild within the FDA.

$SAVA once again we got fu*ked by the evil BIIB + FDA.

$SAVA THIS is how corrupt our FDA and state medical boards are.

$BIIB $SAVA  
I tell ya why - FDA is corrupt deep in its root, period!

Biogens drug really lowered the bar for everyone in the industry which is great..

$SAVA Simufilam - can meet the &quot;biggest&quot; unmet need in the pharmaceutical industry of this century!

Hell, no state income tax, why wouldn’t the outsiders haven there, and it’s warm like their country , and you can pack heat , like their country !!!

business-result

But the company actually has never seen before wonderful results.

And, make no mistake, the result are impressive.

It is the best results that have been seen in AD.

This could be huge in eliminating artificial FUD against the top-line results.

$SAVA Market is moving higher as SAVA is expecting data results.

Anavex is late like the sun comes up and still produces great results.

MOST IMPORTANTLY, THE RESULTS MUST HAVE BEEN GOOD AND PROMISING at each snapshot that leads Remi to use the word &quot;Thrilled&quot; in Dec 6 PR.

Data tells me no safety issues, with a possible large therapeutic window.

Then they dropped the “good” totally “not disappointing” data that Remi was so “Thrilled” about.

This will go beyond parabolic on good data … literally no shares out there unless they offer new ones … $MDGL $VKTX $SLS $SAVA

SAVA data gets analyzed by multiple different labs and shows its cognition improvement in mild AD cases, safe and well-tolerated

$SAVA I love not being able to hold $28 off data that will keep it pinned here until 2024.

but the data to date would predict continued efficacy that will be nigh on impossible to ignore.

$SAVA Institutional buying says data is good!! !

I’ll keep buying until data comes out…

Excited for the next data unveiling….bring it on!

$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”

This will bring in billions of revenue and it will make the life quality longer for AD patients.

This sub-set of patients improved -4.96 mean points on ADAS-Cog from baseline to month 12.

CURING LEUKEMIA isn&#39;t a fly by night thing with Gamma T Cells and they already have ONE COMPLETE RESPONSE curing someone in Stage 4 nonresponsive to other treatments!

$SAVA this is going to be game changer and first drug to give some relief to AD patients … and will make $BIIB poison AD pills an obsolete

The high number of the patients that went into CMS (which is 80% complete) is reassuring.

but reverses cognitive decline and improves quality of life for the patient AND the FAMILY!

but mostly new hope for all the families and patients with AZ.

Testing still continues, so in my way of thinking the real-world results in patients must be nothing short of excellent.

Quicklogic Corp

This month, SensiML was also recognized by leading electronics industry portal in China with over 1 million registered members who voted SensiML solution with on Semi as most innovative value product award.

we probably rally into the close as next few weeks look hopeful with those selling for losses in late December now able to buy back for tax reasons.

customer

Heritage remains strong and has assured its customers that it is not facing any of the ongoing challenges that affected SVB.

I am very pleased to share for the first time that we have taped out a new device that incorporates our eFPGA IP for a customer.

SensiML ecosystem continues to gain momentum with growing new customer and partner interest.

service

We have the capability to offer a full spectrum of solutions from eFPGA IP all the way to full chip designs that incorporate that IP.

&quot;Together we&#39;ve delivered a world-class solution and we&#39;re pleased to see that effort being recognized with this Outstanding Innovation Award.&quot;

chip

wonderful time to be an $AMD stockholder.

Generally positive for QUIK, $NVDA, and others. https://semiengineering.com/what-does-2023-have-in-store-for-chip-design/

And it has a greater margin growth due to its unique combination of chips, software, IP, and royalties. It&#39;s a dream

$QUIK $QQQ $AMD $NVDA $AVGO Nice move today by many semis.

$QUIK So indeed $AMD came in with strong results and forecasts for its programmable chip segment.

A good sign for $QUIK earnings and for the $XLNX part of $AMD business which should also benefit from cost and revenue synergies in the second half of the year.

Chinese chip businesses to see double-digit growth annually since the market is worth tens of billions of dollars.

SensiML is having its best year ever and will make $INTC regret abandoning them. .

Oramed Pharmaceuticals, Inc

I&#39;ve been investing in the medical industry for years and believe this will be a big winner.

$PBLA $ORMP $SLS $TCBP  
 
If you hate money and want a tax write off, I strongly suggest buying these 💩 biopharms.

bounce

$ORMP cash equivalent is $3.50 😆 
will perform similar to VERA and bounce up to $3.-$4 within a week in my opinion good luck 🍀

$ORMP bank your bounce in $KTTA where things are looking up

Top Stocks matching your search for "industry tax"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Jan, 6, 2023

Oct, 6, 2022

QUIK

Quicklogic Corp

-12.03%

$5.82 - $5.12

Feb, 16, 2023

Nov, 12, 2022

ORMP

Oramed Pharmaceuticals, Inc

8.29%

$2.05 - $2.22

Nov, 14, 2022

SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Jan, 6, 2023

Oct, 6, 2022

QUIK

Quicklogic Corp

-12.03%

$5.82 - $5.12

ORMP

Oramed Pharmaceuticals, Inc

8.29%

$2.05 - $2.22